Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children

Study Overview
=================
Brief Summary
-----------------
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic. ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising. The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017. Few clinical data have been published so far concerning the French population. The investigators would like to build a database so that the investigators can publish our results and share our experience.

Official Title
-----------------
Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children. MYOPSTOP

Conditions
-----------------
Myopia, Children

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with active myopia treated with ATROPINE 0.01% eye drops patient affiliated with a social security organization agreement of both parents Exclusion Criteria: non compliance with treatment

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with active myopia treated with ATROPINE eye drops<br> | Other: data collection<br>* Demographic data: age, sex Ophthalmological history: refraction of parents, previous refractions Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics Potential undesirable events (halos, photophobia...)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| previous refractions | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| refraction of parents | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| intra-ocular pression | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| objective refraction after fog | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| cycloplegia with SKIACOL | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| slit lamp | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| dilated eye exam | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 
| biometrics | effectiveness of ATROPINE 0.01% eyedrops in our current clinical practice | every 6 months up to age 18 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| undesirable events collection | measured the tolerance of ATROPINE 0.01% eyedrops. Number of participants with treatment-related adverse events. | every 6 months up to age 18 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atropine